Navidea Biopharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and radiopharmaceutical therapeutics designed to guide disease management. The company’s lead product, Lymphoseek® (technetium Tc 99m tilmanocept), is an FDA‐approved lymphatic mapping agent used during surgical procedures to identify sentinel lymph nodes in breast cancer and melanoma patients. Navidea’s platform leverages proprietary targeting molecules that bind to specific biomarkers, enabling high‐resolution imaging and targeted delivery of therapeutic radioisotopes.
In addition to its marketed product, Navidea maintains an active pipeline of investigational radiopharmaceuticals in oncology, immunology and neurology. The company is advancing candidates aimed at improving early detection of Alzheimer’s disease through tau PET imaging, as well as investigational therapies for inflammatory and infectious diseases. These programs employ site‐specific binding technologies to concentrate diagnostic or therapeutic payloads at disease sites, minimizing off‐target exposure and enhancing clinical utility.
Originally incorporated in Delaware in the mid‐1990s under a different name, the company rebranded as Navidea Biopharmaceuticals in 2013 following its acquisition of lymphatic mapping assets from Cardinal Health. Headquartered in Dublin, Ohio, Navidea operates research and development facilities in the United States and collaborates with academic and industry partners to support global clinical trials and pursue regulatory approvals outside North America.
Under the leadership of President and Chief Executive Officer Michael H. Koren, Navidea continues to expand its manufacturing capabilities and strengthen its intellectual property portfolio. The company’s strategic focus on precision imaging and targeted radiotherapeutics reflects a commitment to advance patient care through innovative diagnostic tools and novel treatment modalities.
AI Generated. May Contain Errors.
Free NAVB Stock Alerts